Top pharmaceutical sales company Vanguard Pharmaceuticals has the possibility of acquiring a sales contact for the recently developed swine flu vaccine.

Crucell NV is currently developing the only adjuvanted flu vaccine against the influenza virus licensed for all age groups but Crucell stock hasn’t match analyst expectations showing a 20% increase since April 2009.

With two forms of influenza vaccine, BioCryst Pharma has the potential to emerge as one of the world’s top biotech companies in the fight against the swine flu. BioCryst stock has increase 450% since April 2009 reaching the best swine flu stock performed: Novavax NVAX with a 500% plus during the same period.

The 500% plus increase of Novavax share price since the swine flu symptoms invaded the media, puts this company at the peak of the high-yielding list of stocks to watch, but also, at the highest risk. For how much longer will Novavax Pharmaceuticals be able to sustain the share price?

AstraZeneca’s swine flu research is continuing to combat the mutating forms of the swine flu virus. AstraZeneca’s continuing efforts to produce and distribute the first swine flu vaccine may force it to join venture with top biotech companies participating in the swine flu research. Swine stocks to watch: AVI Biopharma (AVII), Quidel Corporation (QDEL), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX) and Dynavax Technologies (DVAX).